Mefenamic acid - Generic Drug Details

What are the generic drug sources for mefenamic acid and what is the scope of patent protection?

Mefenamic acid is the generic ingredient in two branded drugs marketed by Belcher, Chartwell Rx, Lupin Ltd, Micro Labs, Nostrum Labs Inc, and Avion Pharms, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for mefenamic acid. Six suppliers are listed for this compound.

Summary for mefenamic acid

US Patents:	0
Tradenames:	2
Applicants:	6
NDAs:	6
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	134
Clinical Trials:	16
Patent Applications:	7,077
Drug Prices:	Drug price trends for mefenamic acid
What excipients (inactive ingredients) are in mefenamic acid?	mefenamic acid excipients list
DailyMed Link:	mefenamic acid at DailyMed

See drug prices for mefenamic acid

Recent Clinical Trials for mefenamic acid

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Takeda	Phase 1
Nuventra	Phase 1
Emalex Biosciences Inc.	Phase 1

See all mefenamic acid clinical trials

Pharmacology for mefenamic acid

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

Medical Subject Heading (MeSH) Categories for mefenamic acid

Anti-Inflammatory Agents, Non-Steroidal

Cyclooxygenase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for mefenamic acid

M01AG	Fenamates
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

US Patents and Regulatory Information for mefenamic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avion Pharms	PONSTEL	mefenamic acid	CAPSULE;ORAL	015034-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Chartwell Rx	MEFENAMIC ACID	mefenamic acid	CAPSULE;ORAL	209209-001	Sep 18, 2020		DISCN	No	No
Lupin Ltd	MEFENAMIC ACID	mefenamic acid	CAPSULE;ORAL	091322-001	Jul 22, 2011	AB	RX	No	No

Mefenamic acid Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Mefenamic Acid

Introduction to Mefenamic Acid

Mefenamic acid, a non-steroidal anti-inflammatory and analgesic-antipyretic drug, is widely used for the relief of postoperative traumatic inflammation, rheumatoid arthritis, and other pain-related conditions. Its market has been experiencing significant growth, driven by various factors.

Market Size and Growth Projections

The global mefenamic acid market is poised for substantial expansion from 2023 to 2031. According to recent market research, the market size is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.00% from 2024 to 2031, reaching a significant value in USD million by the end of the forecast period[4].

Segmentation of the Mefenamic Acid Market

The market is segmented based on several key factors:

Type

• Patent: This segment includes proprietary formulations of mefenamic acid.
• Generic: Generic versions of mefenamic acid, which are more affordable and widely available[1].

Application

• Hospital: Usage in hospital settings for various medical treatments.
• Drug Store: Retail sales through pharmacies and drug stores.
• Online: Sales through online platforms, which have seen a surge due to increased e-commerce activity[1].

Geographical Regions

• North America: Holds a major market share, with a CAGR of 3.2% from 2024 to 2031.
• Europe: Accounts for over 30% of the global revenue, with a CAGR of 3.5% from 2024 to 2031.
• Asia-Pacific: The fastest-growing region, driven by rising healthcare awareness and increasing access to medications, with a CAGR of 7.0% from 2024 to 2031.
• Latin America: Expected to grow at a CAGR of 4.4% from 2024 to 2031.
• Middle East and Africa: Growing at a CAGR of 4.7% from 2024 to 2031[4].

Drivers of Market Growth

Several factors are driving the growth of the mefenamic acid market:

Increasing Demand for Pain Relief

The rising prevalence of chronic pain conditions and the need for non-opioid pain management options are significant drivers. As populations become more health-conscious, the demand for effective pain relief solutions like mefenamic acid is increasing[4].

Advancements in Drug Formulations

Improvements in drug formulations have enhanced the efficacy and safety of mefenamic acid, making it a preferred choice for patients and healthcare providers. These advancements are expected to boost sales and market growth[4].

Government Initiatives and Healthcare Infrastructure

Government initiatives aimed at enhancing healthcare access and affordability, particularly in emerging economies, are supporting market growth. Investments in healthcare infrastructure have improved the availability and distribution channels for pharmaceutical products[4].

Challenges and Restraints

Despite the growth, the mefenamic acid market faces several challenges:

Physicochemical Properties

Mefenamic acid has poor solubility, hydrophobicity, and a tendency to stick to surfaces, which poses problems in granulation, tableting, and dissolution. These properties require careful handling and formulation adjustments[2].

Polymorphic Behavior

Understanding the polymorphic behavior of mefenamic acid is crucial for drug development. Different forms of the drug can affect its stability and solubility, impacting its development potential[2].

Competitive Landscape

The competitive landscape of the mefenamic acid market is diverse and dynamic:

Key Players

Companies such as Shionogi Pharma, Solitaire Pharmacia, Shinto Organics, Captab, EMS Pharma, and others are prominent in the market. These companies are involved in various activities including new product introductions, collaborations, mergers, and acquisitions[1].

Regional and Industry Footprint

The market is characterized by a strong presence of both established and emerging players. Companies are expanding their regional and industry footprint to align with market trends and consumer demands[1].

Financial Trajectory

The financial outlook for the mefenamic acid market is robust:

Revenue Projections

The global market size is expected to grow significantly, with North America holding a major share of the global revenue. The Asia-Pacific region is anticipated to be the fastest-growing segment due to rising healthcare awareness and increasing access to medications[4].

CAGR by Region

• North America: 3.2%
• Europe: 3.5%
• Asia-Pacific: 7.0%
• Latin America: 4.4%
• Middle East and Africa: 4.7%[4].

Emerging Trends and Opportunities

Several emerging trends are shaping the future of the mefenamic acid market:

Technological Advancements

Advances in crystallization kinetics and population balance modeling are improving the efficiency and quality of mefenamic acid production. These technological advancements help in optimizing the nucleation and growth kinetics of the drug[2].

Changing Lifestyle Patterns

The increasing prevalence of chronic pain conditions due to changing lifestyle patterns is fueling the demand for non-opioid pain management options like mefenamic acid[4].

Conclusion

The mefenamic acid market is poised for significant growth driven by increasing demand for pain relief, advancements in drug formulations, and government initiatives. Despite challenges related to its physicochemical properties, the market is expected to expand substantially over the forecast period.

Key Takeaways

• The global mefenamic acid market is projected to grow at a CAGR of 5.00% from 2024 to 2031.
• The Asia-Pacific region is the fastest-growing segment due to rising healthcare awareness and increasing access to medications.
• North America and Europe hold significant market shares, with CAGRs of 3.2% and 3.5%, respectively.
• Advancements in drug formulations and government initiatives are key drivers of market growth.
• The market faces challenges related to the physicochemical properties of mefenamic acid.

Frequently Asked Questions (FAQs)

Q: What is the expected CAGR of the global mefenamic acid market from 2024 to 2031? A: The global mefenamic acid market is expected to grow at a CAGR of 5.00% from 2024 to 2031[4].

Q: Which region is the fastest-growing segment in the mefenamic acid market? A: The Asia-Pacific region is the fastest-growing segment, driven by rising healthcare awareness and increasing access to medications[4].

Q: What are the main challenges faced by the mefenamic acid market? A: The main challenges include poor solubility, hydrophobicity, and a tendency to stick to surfaces, which affect granulation, tableting, and dissolution[2].

Q: Who are some of the key players in the mefenamic acid market? A: Key players include Shionogi Pharma, Solitaire Pharmacia, Shinto Organics, Captab, EMS Pharma, and others[1].

Q: How do government initiatives impact the mefenamic acid market? A: Government initiatives aimed at enhancing healthcare access and affordability support market growth by improving the availability and distribution channels for pharmaceutical products[4].

Cited Sources:

1. Market Research Intellect - Global Mefenamic Acid Market Size, Scope And Forecast Report[1].
2. SCIRP - Optimum Kinetic Parameters of Mefenamic Acid Crystallization by PBM[2].
3. PubMed - Dual effects of mefenamic acid on the IKs molecular complex[3].
4. Cognitive Market Research - Mefenamic Acid Market Report 2024 (Global Edition)[4].